Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company have announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
The Class 1 resubmission follows a complete response letter issued by the FDA that referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.
The FDA did not ask Boehringer Ingelheim to complete any new clinical trials to support the approval of the application.
Boehringer Ingelheim Pharmaceuticals president and CEO Paul Fonteyne said that the company is very pleased to move forward with resubmission of the empagliflozin NDA following a FDA inspection of the Boehringer Ingelheim facility referenced in the complete response letter.
"We believe in the potential of empagliflozin and hope to provide another treatment option in the near future to adults with type 2 diabetes," Fonteyne added.
Empagliflozin is an investigational SGLT2 inhibitor being studied for the reduction of blood glucose levels in adults with diabetes. The SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.
Empagliflozin was studied in one of the largest clinical trial programs in its class, comprised of more than ten multinational clinical trials and more than 13,000 adults with type 2 diabetes.